The cells expressing wild-type SMARCA4 were not simply less sensitive to inhibitors of mitosis, as all of these NSCLC cell lines were similarly sensitive to the depletion of PLK1. We further measured the cell doubling times of 26 NSCLC and HBEC lines used in this study, but we did not observe a statistically significant difference (P=0.08, one-way analysis of variance (ANOVA) and post hoc Dunnett's multiple comparison tests) in the average doubling times between SMARCA4-null and SMARCA4-wild-type NSCLC lines (Supplementary Table 1). The gene discussed is PLK1; the disease is non-small cell lung carcinoma.